JP2024507937A5 - - Google Patents
Info
- Publication number
- JP2024507937A5 JP2024507937A5 JP2023551762A JP2023551762A JP2024507937A5 JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5 JP 2023551762 A JP2023551762 A JP 2023551762A JP 2023551762 A JP2023551762 A JP 2023551762A JP 2024507937 A5 JP2024507937 A5 JP 2024507937A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159698.6 | 2021-02-26 | ||
| EP21159698 | 2021-02-26 | ||
| US202163166339P | 2021-03-26 | 2021-03-26 | |
| US63/166,339 | 2021-03-26 | ||
| US202163274709P | 2021-11-02 | 2021-11-02 | |
| US63/274,709 | 2021-11-02 | ||
| EP21211114.0 | 2021-11-29 | ||
| EP21211114 | 2021-11-29 | ||
| PCT/EP2022/054993 WO2022180271A1 (en) | 2021-02-26 | 2022-02-28 | Antibodies that bind CD123 and gamma-delta T cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024507937A JP2024507937A (ja) | 2024-02-21 |
| JPWO2022180271A5 JPWO2022180271A5 (https=) | 2025-02-27 |
| JP2024507937A5 true JP2024507937A5 (https=) | 2025-02-27 |
Family
ID=80786427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551762A Pending JP2024507937A (ja) | 2021-02-26 | 2022-02-28 | Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240141071A1 (https=) |
| EP (1) | EP4298125A1 (https=) |
| JP (1) | JP2024507937A (https=) |
| KR (1) | KR20230169950A (https=) |
| AU (1) | AU2022225091A1 (https=) |
| BR (1) | BR112023017099A2 (https=) |
| CA (1) | CA3209454A1 (https=) |
| MX (1) | MX2023009950A (https=) |
| WO (1) | WO2022180271A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2025012118A2 (en) * | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| CN118496370A (zh) * | 2024-06-07 | 2024-08-16 | 南方医科大学深圳医院 | 一种靶向alox5纳米抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| EP3129404B1 (en) * | 2014-04-10 | 2026-01-28 | LAVA Therapeutics N.V. | Immunoglobulins binding human vgamma9vdelta2 t cell receptors |
| BR112020020604A2 (pt) * | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| WO2020060406A1 (en) * | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| JP2022532868A (ja) * | 2019-05-04 | 2022-07-20 | インヒブルクス インコーポレイテッド | Ｃｄ１２３結合性ポリペプチド及びその使用 |
| EP3965818A4 (en) | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY |
-
2022
- 2022-02-28 MX MX2023009950A patent/MX2023009950A/es unknown
- 2022-02-28 WO PCT/EP2022/054993 patent/WO2022180271A1/en not_active Ceased
- 2022-02-28 CA CA3209454A patent/CA3209454A1/en active Pending
- 2022-02-28 JP JP2023551762A patent/JP2024507937A/ja active Pending
- 2022-02-28 US US18/278,956 patent/US20240141071A1/en active Pending
- 2022-02-28 KR KR1020237032819A patent/KR20230169950A/ko active Pending
- 2022-02-28 EP EP22708159.3A patent/EP4298125A1/en active Pending
- 2022-02-28 AU AU2022225091A patent/AU2022225091A1/en active Pending
- 2022-02-28 BR BR112023017099A patent/BR112023017099A2/pt unknown